A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

New research employing mRNA technology — which gained prominence during the COVID-19 pandemic — may offer the key to developing a cure for HIV. One of the chief challenges in combating HIV is the ...

Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...